Navigation Links
INVO Bioscience Announces First Shipments of INVOcell Into Bolivia

BEVERLY, Mass., Dec. 21, 2010 /PRNewswire/ -- INVO Bioscience, Inc. (OTC Bulletin Board: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced the initial shipments of the INVOcell device into Bolivia.  The initial order of INVOcell devices was purchased by The National Center for Fertility and Sterility (CENALFES). Under the direction of clinic director Dr. Joaquin Lopez Arana and embryologist Dr. Patricia Frias, CENALFES is the largest infertility treatment center in Bolivia, having assisted more than 4,000 infertility patients over the past 20 years resulting in more than 1,500 births. Bolivia represents the fourth country in South America where fertility clinics have ordered INVOcell.  

Bolivia has approximately 5 fertility centers licensed to perform assisted reproductive procedures.  According to the Bolivian Health Ministry there are more than 1.8 million infertile couples in Bolivia, however less than 1,000 couples per year engage in assisted reproductive procedures, largely due to costs. Clinical results have demonstrated outstanding effectiveness of the INVOcell process without many of the inherent expenses associated with traditional in-vitro fertilization (IVF) procedures.

Kathleen Karloff, chief executive officer for INVO Bioscience, commented, "The company continues to execute on its stated goal of introducing the INVOcell device and process to many of the key opinion leaders throughout the world that will influence expanded acceptance and use of our products.  CENALFES is one the largest providers of infertility treatments in Bolivia, which we expect to become a strong reference to the exceptional capabilities of INVOcell. We look forward to continue working with the many physicians at CENALFES and elsewhere in Bolivia to offer the many suffering infertile patients a cost effective solution to this very unfortunate problem."

INVOcell is registered as a class II device in Bolivia, and therefore according to local laws does not require extended registration. The company continues to market its products in all applicable countries covered by CE Mark or other local accepted criteria.  Additionally, the company has commenced registration processes in China and Ukraine, while continuing to explore additional appropriate countries to begin the registration process to market its products.

INVOcell is CE Mark approved in Europe and Canada and conforms with all consumer health and safety requirements. INVOcell is currently marketed and sold in Austria, Bolivia, Cameroon, Columbia, the Dominican Republic, Guatemala, Nicaragua, Pakistan, Panama, Peru, Spain, Togo, Turkey, and Venezuela.

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit

Private Securities Litigation Reform Act of 1995

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.Contact: Kathleen KarloffINVO Bioscience, Inc.978-878-9505 ext

SOURCE INVO Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Initiates Two Phase I Clinical Trials
2. Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
3. Cell Biosciences Announces US Patent Issuance
4. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
5. ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
11. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)... ) ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... 2015 , ... Trying to relax on a couch can actually be uncomfortable, ... this design due to personal experience with a bad back," he said. , This ... as well as increases support. It also makes it easier to eat, do other ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is ... panels to choose from, the possibilities are endless. Users have full control over angle ... ProPanel: Pulse masking effects, users are sure to get heads to turn. , ProPanel: ...
(Date:11/27/2015)... ... , ... According to an article published November 13th on, ... D.C. revolved around the fact that proper dental care, both at-home and in the ... between periodontal disease (more commonly referred to as gum disease) and diabetes. According to ...
(Date:11/27/2015)... CO (PRWEB) , ... November 27, 2015 , ... According ... cities are not changing the way that they are handling security in light of ... police and security presence in an attempt to stop an attack from reaching U.S. ...
(Date:11/27/2015)... ... 27, 2015 , ... A team of Swiss doctors has released a report ... has just posted the findings on the website. Click here to read the ... 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the ...
Breaking Medicine News(10 mins):